NinePointTwo Capital’s Editas Medicine EDIT Stock Holding History

NinePointTwo Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27,832	Closed	-$201K	–	273
2023 Q1	$201K	Buy	27,832 +14,235	+105%	+$127K	0.08%	221
2022 Q4	$120K	Buy	+13,597	New	+$149K	0.05%	171

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

NinePointTwo Capital's EDIT Position: Q2 2023 in Review

NinePointTwo Capital sold out of Editas Medicine (EDIT) in Q2 2023, closing a stake of 27,832 shares — an estimated $201K sold.

NinePointTwo Capital first reported a position in EDIT in Q4 2022 and held it in 2 quarters. The position peaked at $201K in Q1 2023. 237 funds tracked by Wall St. Rank hold EDIT as of Q2 2023.

NinePointTwo Capital reported no remaining Editas Medicine position as of Q2 2023 after selling out during the quarter.
NinePointTwo Capital sold 27,832 Editas Medicine shares in Q2 2023, an estimated $201K.
NinePointTwo Capital first reported a position in Editas Medicine in Q4 2022 and held it in 2 quarters.
NinePointTwo Capital's Editas Medicine position peaked at $201K in Q1 2023.
237 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2023.

Based on NinePointTwo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.